StemCell Therapy

Stephen Curry is undoubtedly the greatest shooter of all time but he suffers from a genetic eye disease with no known cure.

When we say Stephen Curry is one of a kind, we mean it. Every other player in the league current or past has a parallel.

Take Shaquille ONeal for example. The 71 center was perhaps one of the most dominant players ever. Yet, he himself believes Giannis Antetokounmpo is a close comparison to him in the modern-day game.

But when it comes to Curry, there is no alternative to him. No one can shoot as consistently as him or run through screens all day, or drive to the ring the way he does. Its the complete package of Stephen Curry that overwhelms opponents.

Contrary to what fans would believe, though his lethal from beyond the arc, three-point shooting is not the pillar of his game. It is in fact his ability to use any aspect of his game on any given night.

Three-pointers not landing? Curry just drives to the rim. Getting bodied by bigger players? He stays in constant motion to beat defenders.

On top of his scoring abilities, Steph is an exceptional court general. His playmaking is second to none. The vision to find open shooters or thread the needle through busy lanes, make the Chef one of the most valuable assets in league history.

But unfortunately, there is a high probability Stephen Curry may lose his eyesight.

Also read: Michael Jordan, who reportedly wants to sell $1.57 Billion Charlotte Hornets, entrusts his right-hand man with new contract

Its ironic that Stephen Curry, the greatest shooter of all time, suffers from an untreatable eye condition. In Keratoconus, a chronic disease that cannot be treated, the cornea bulges outwards like a cone.

This impacts how light is perceived by the eye causing blurred vision and incapability to read or drive.

Curry found out about the disease in 2019 after a shooting slump. Curry addressed the poor performance by getting contact lenses.

Though the lenses have helped the 4-time NBA Champ see the board clearly, it does not automatically make his eyes better.

The issue with Keratoconus is that it never goes away. Stephs natural vision will always remain blurred. In fact, Keratoconus progressively gets worse as time passes by.

Also read: In 7-years LeBron James will be eligible for pension and not get it: Kendrick Perkins gives his list of top 5 players

The rest is here:
Stephen Curry, whose $185,000 worth vehicle almost took his life, is sure to lose his eyesight due to a genetic defect - The Sportsrush

Donny W. Suh, MD, FAAP, MBA, FACS, Chief of Pediatric Ophthalmology and Strabismus, and Professor, Department of Ophthalmology and Visual Science, Gavin Herbert Eye Institute, University of California, Irvine, named recipient of the 8th Annual Bonnie Strickland Champion for Children's Vision Award from the National Center for Children's Vision and Eye Health at Prevent Blindness.

CHICAGO, Sep. 27, 2022 /PRNewswire-PRWeb/ -- The National Center for Children's Vision and Eye Health at Prevent Blindness (NCCVEH) has announced the recipient of the eighth annual "Bonnie Strickland Champion for Children's Vision Award" as Donny W. Suh, MD, FAAP, MBA, FACS, Chief of Pediatric Ophthalmology and Strabismus, and Professor, Department of Ophthalmology and Visual Science, Gavin Herbert Eye Institute, University of California, Irvine. The award will be formally presented at the NCCVEH Annual Meeting, to be held virtually, on Friday, Oct. 14, 2022.

The Bonnie Strickland Champion for Children's Vision Award recognizes significant efforts by an individual or group of individuals to improve public health approaches for children's vision and eye health at the state or national level. The award was established in 2014 by the Advisory Committee of the National Center for Children's Vision and Eye Health at Prevent Blindness to honor Bonnie Strickland and her groundbreaking work to establish a comprehensive system for children's vision in the U.S. She served as Director of the Division of Services for Children with Special Health Needs, Maternal and Child Health Bureau, before her retirement in 2014.

Dr. Suh has been named as the 2022 Bonnie Strickland Champion for Children's Vision Award recipient in recognition of his unique approach to connecting vision to overall health by aligning pediatrics and eye care; reducing barriers to eye care and improving vision health equity; and his participation in critical research that advances understanding of children's vision and eye health as well as vision disorders. Dr. Suh conducted research on school attendance and performance for children screened through the UC Irvine Mobile Eye Clinic, which will enhance the field's understanding of the connection of vision to academic success.

Dr. Suh currently serves as medical director of the UC Irvine Mobile Eye Clinic. The van began making school visits seven years ago and has provided vision screening for more than 20,000 preschoolers in Orange County, Calif. Since his appointment at UC Irvine, Dr. Suh, has increased fundraising efforts and success for this community outreach, as he did with a similar pediatric vision van program at his former institution, the University of Nebraska Medical Center, where more than 3,500 children were evaluated and treated each year.

Dr. Suh is also being recognized for his important work in training pediatric ophthalmologists and his leadership within the American Academy of Pediatrics for improving communications between the fields of pediatrics and ophthalmology, and developing vision screening guidelines.

"I am truly honored and humbled to be recognized by the NCCVEH as the Bonnie Strickland Champion for Children's Vision Award. Bonnie is an inspirational figure and a true champion advocating for our children's vision. Vision Screening programs have been a team effort from the public health sector, educators, school nurses, and community stakeholders, to make our dreams come true with a single vision," said Dr. Suh. "Also, there have been many people before me who dedicated tremendous sacrifices to make these programs possible. I would like to share this award with my Pediatric Eye Mobile team and the predecessors who made it possible. As Henry Ford once said, 'Coming together is the beginning. Keeping together is progress, and working together is success!'"

"Prevent Blindness has declared 2022 as 'The Year of Children's Vision," and we thank Dr. Donny Suh for his exemplary efforts and decades-long dedication to providing children with the access to quality eyecare services they deserve," said Jeff Todd, president and CEO if Prevent Blindness. "We enthusiastically congratulate Dr. Suh for being named the recipient of this year's Bonnie Strickland Champion for Children's Vision Award and look forward to working with him to continue his sight-saving efforts!"

Past recipients of the Bonnie Strickland Champion for Children's Vision Award include Shavette L. Turner, vice president, Children's Vision Services at Prevent Blindness Georgia; Logan Newman, founder of the East High School Vision Care Program; Anne L. Coleman, MD, MPH, UCLA Stein Eye Institute; the Vision in Preschoolers (VIP) Study Group; Richard Bunner, retired from the Ohio Department of Health; Sean P. Donahue, MD, PhD, Professor of Ophthalmology and Visual Sciences at Vanderbilt University; the Illinois Eye Institute (IEI) at Princeton Vision Clinic; and the Pediatric Physicians' Organization at Children's. For more information on the 2022 Bonnie Strickland Champion for Children's Vision Award, Prevent Blindness or the NCCVEH, please visit nationalcenter.preventblindness.org or contact Donna Fishman at dfishman@preventblindness.org.

About the National Center for Children's Vision and Eye Health at Prevent Blindness Founded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. In 2009, Prevent Blindness established the National Center for Children's Vision and Eye Health, with funding and leadership support from the HRSA- Maternal and Child Health Bureau. Serving as a major resource for the establishment of a public health infrastructure, the National Center advances and promotes children's vision and eye care, providing leadership and training to public entities throughout the United States. The National Center is advised by a committee of national experts and leaders from the fields of ophthalmology, optometry, pediatrics, nursing, family advocates and public health to guide the work and recommendations of the Center. For more information, or to make a contribution to the sight-saving fund, call (800) 331-2020, or visit us at https://nationalcenter.preventblindness.org/.

###

Media Contact

Sarah Hecker, Prevent Blindness, 312.363.6035, shecker@preventblindness.org

Twitter

SOURCE NCCVEH

See the original post:
NCCVEH Names Dr. Donny W. Suh, Gavin Herbert Eye Institute, UC Irvine, as Recipient of the 8th Annual Bonnie Strickland Champion for Children's Vision...

We have a game-changing offering for how people access and experience employee benefits - with an ultimate goal to positively impact hundreds of millions of lives through high-quality, accessible and affordable health benefits.

SAN CARLOS, Calif. (PRWEB) September 28, 2022

XP Health, the company creating the first digital-first vision benefits platform, today announces a $17.1M Series A round led by HC9 Ventures, Valor Capital Group and ManchesterStory. Additional investors include Canvas Ventures, CameronVC, Core Innovation Capital, GSR Ventures, and Plug and Play, as well as high profile angels like Ken Goulet (former EVP Anthem), Kevin Hill (former regional CEO United Healthcare), Jeff Epstein (CFO of Oracle, partner at Bessemer Venture Partners) and Brett Rochkind (former managing partner General Atlantic). This expansion capital will bolster XP Healths drive to reinvent how people experience vision benefits.

XP Health offers a high-quality, innovative vision care benefit that doubles the value of coverage while reducing costs by half for members. This recent fundraise follows a successful 2021 for the company, during which it raised $5.5 million and was named one of Fast Companys Most Innovative Companies. Starting with just 30 clients last year, XP Health now services 1,500, including high-profile companies like Docusign, Chegg, Navistar, Sequoia Consulting, and strategic partners Guardian Life Insurance and The Health Benefit Alliance. All-in, XP Health covers more than 250,000 people.

Through its integrated supply chain, XP Health keeps costs low by removing the middlemen that add significant markups at several steps in the process. This business model has helped triple vision benefits coverage for employees while reducing their out-of-pocket costs by 80 percent, all while cutting employer eyewear claim costs by 40 percent. This model has also helped the company to grow their revenue by 9,300 percent since January 2021.

This round of funding enables us to strengthen the platforms functionality and provide a stellar consumer experience in the most affordable way to employers, insurance carriers, and employees, said Antonio Moraes, Co-Founder, and CEO of XP Health and a former impact venture capital investor. We have a game-changing offering for how people access and experience employee benefits - with an ultimate goal to positively impact hundreds of millions of lives through high-quality, accessible, and affordable health benefits.

Vision coverage has remained static, complicated, expensive, and unsatisfying for decades. An estimated 93 million adults in the United States (about 25 percent of the population) are at high risk for serious vision loss, but only half visited an eye doctor in the past 12 months [1]. XP Health uses advanced technology to transform vision care into something people - whether they have 20/20 eyesight or need a prescription - are excited to use, and has a unique business model that lowers costs for all parties.

The XP Health team is bringing some much-needed change to vision benefits. HC9 is excited to leverage our experience and network to help XP Health accelerate growth while improving eye health, said Jon Gordon, General Partner of HC9 Ventures. We know firsthand what it is like to operate and grow businesses that are driving health innovation, and XP Health is the perfect partner.

We believe that XP Health will fundamentally transform the future of vision benefits and are thrilled to contribute to their mission to innovate in the space, said Michael Nicklas of Valor Capital Group. XP Health is working hard towards expanding access to high quality vision care to millions of employees in the United States and we are proud to have backed the company since day one.

As an insuretech-focused investor, we know that quality benefit programs make a big difference in a companys ability to attract and retain employees, which is especially important given the current state of the job market, said David Miles of ManchesterStory. XP Health is on a path to make vision care a 'must have' core employee benefit. Our confidence in XP Healths founding team and their passion for the end-consumer made XP Health an investment opportunity we could not pass up.

About XP HealthXP Health democratizes access to high-quality, delightful experiences in vision care that double coverage and reduce costs by half. It is the first modern vision platform focused on eye care and eyewear that can be used to enhance or replace existing vision plans, and uses artificial intelligence, augmented reality, and customer-centric design to create a stellar member experience. XP Health was named to the 2021 Fast Company list of the Worlds Most Innovative Companies and over the past year has expanded from 30 to 1500+ customers, including Docusign, Palantir, Chegg, Sequoia Consulting, and strategic partner Guardian Life Insurance. To learn more visit xphealth.co.

About HC9HC9 is an early-stage venture capital firm purpose-built to provide industry-specific expertise to emerging healthcare software and services companies. HC9s unparalleled, deeply-engaged investor community of leading executives, entrepreneurs, and investors collectively has thousands of years of experience in all facets of healthcare. We leverage the power of that experience to support the founders that are shaping the future of healthcare. For more information, please visit http://www.hc9.vc.

About Valor Capital GroupValor Capital Group is a global venture capital firm, focused on early-stage and growth equity investments. Currently, the Group has over $2 billion AUM, distributed across six funds. Valor pursues a cross-border strategy with a focus primarily in Brazil and throughout Latin America, as well as investing in international companies and helping them expand into the region. Since inception, the Firm has invested in over 100 companies, 20 of which are unicorns.

About ManchesterStoryManchesterStory partners with world-class founders pursuing technological innovation in InsurTech and adjacent sectors. Focused on early-stage start-ups, ManchesterStory leads venture capital investments to fund growth while also connecting them with leading financial services companies across North America and beyond.

[1] https://www.cdc.gov/visionhealth/resources/publications/high-risk-vision-loss.html#:~:text=In%202017%2C%20approximately%2093%20million,exam%20in%20the%20last%20year.

Share article on social media or email:

More:
XP Health Raises $17.1M Series A to Transform Vision Benefits for Insurance Carriers, Companies and Employees - PR Web

four a day 28/09/2022 9:02 pm

ocular herpes

Ringworm is a rash that appears as small blisters on the skinusually on the torso, although it can also appear on the abdomen, legs or face, and is caused by reactivation of the chickenpox virus. smallpox virus as if sleeping in our body, but After years it reactivates and herpes zoster infection appears.,

One of the existing types of herpes zoster is ophthalmic:

Redness of the eye.

Foreign body sensation.

Constant tearing.

{{ #leaves }}

{{#section.link.href}} {{section.link.title}} {{/section.link.href}}

{{ /leaves }}

-Photophobia or sensitivity to light.

-Low vision if shingles affects the retinal area.

Rash or swelling on the eyelids.

If the herpes reaches the cornea, then the scars can be seen

If the disease is not treated May continue to progress manifesting as corneal ulcers, In more advanced stages, the herpes virus can seriously damage the cornea, even perforating it. It usually affects only one eye.

Once a diagnosis is made by an ophthalmologist, treatment will aim to treat the symptoms and prevent new episodes. For this, Adequate eye hygiene with physiological serum will be done daily and antiviral and anti-inflammatory drugs will be prescribed,

In extreme cases, if ocular herpes has caused significant loss of vision due to damage to the cornea, a corneal transplant may be a solution.

Systemic treatment of herpes zoster shortens the healing process, preventing or relieving pain and other complications Acute or chronic, especially when administered within the first 72 hours of symptoms.

The most frequent complications of herpes zoster ophthalmicus are those affecting the eyelid skin (blepharitis) and/or the conjunctiva (conjunctivitis). Involvement of the cornea (keratitis) is most severe and can leave sequelae affecting vision. other thing, Intrauterine inflammation can produce sequelae such as cataracts or glaucoma and inflammation of the retina (retinitis) Can skip important sequences,

Although this type of shingles can have different results., Carmen suffered from this ringworm: It affected my eyesight and I lost a lot of vision. Now I have monocular vision and my eyes are very tired, he explained. I would tell people suffering from this to go to the doctor immediately because you can prevent the nerve from being affected as it happened to me.

The average duration of shingles is 2 to 4 weeks, It can be reduced if treatment is applied with the first symptoms. For this reason, it is very important to go to the doctor as soon as the pain starts or as soon as the first blisters appear.

Herpes zoster has a low mortality rate, but its complications, especially postherpetic neuralgia, can cause disability and affect the quality of life of people suffering from it, There is no cure for this disease, but it is preventable. For more information consult your doctor and visit the website http://www.virusherpeszoster.com.

See original here:
Everything You Need To Know About Ocular Herpes Zoster: Symptoms, Treatment, And Complications - World Nation News

ZUG, Switzerland and BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130™, the Company’s wholly-owned allogeneic CAR T cell therapy targeting CD70, for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS).

Read this article:
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell...

AGOURA HILLS, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease, Pancreatic Cancer, and DIPG, today announced that the Company will be presenting at the upcoming SITC 37th Annual Meeting, held November 10-12, 2022, in Boston, MA.

Visit link:
Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting

SALT LAKE CITY, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey it conducted on the attitudes, knowledge, and practices related to risk assessment, prevention, and screening for breast and ovarian cancer. The findings reveal disconnects between perceived health knowledge and proactive actions taken in response.

See original here:
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds

TORONTO and HOUSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced new clinical data on anti-tumor activity from the Phase 1/2 ABILITY study of MDNA11, the Company’s “beta-only” long-acting IL-2 super-agonist. These data include a confirmed partial response (PR) in a fourth-line metastatic pancreatic ductal adenocarcinoma (PDAC) patient that had previously failed chemo and checkpoint inhibitor therapies. The confirmatory scan for this patient continues to show further tumor reduction compared to prior scans, suggesting durable anti-cancer activity following MDNA11 monotherapy. Overall, five of fourteen evaluable patients in the ABILITY study’s low and mid-stage dose escalation cohorts have achieved tumor control (PR or stable disease (SD)) with MDNA11 monotherapy.

Go here to see the original:
Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing...

Appointment of Stuart Loesch as President Leverages His Strong Leadership Abilities and Extensive Expertise in Allergy and Pharmaceutical Development

Excerpt from:
Intrommune Expands and Strengthens Senior Leadership Team

NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) --  Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced a new anti-FcRn, IMVT-1402, at Roivant’s Investor Day at 11:00am on September 28, 2022. The presentation can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com.

Follow this link:
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn  

Recognized for pioneering work in field of integrin receptor biology, leading to new treatments for multiple autoimmune disorders

Read more:
Morphic Congratulates Timothy A. Springer, PhD as 2022 Albert Lasker Basic Medical Research Award Honoree

PHILOGEN S.p.A.

Link:
Board of Directors Approves Half-Year Financial Report as of June 30, 2022

WVE-006 is the most advanced candidate for AATD designed to restore functional wild-type AAT protein and reduce Z-AAT protein aggregation with potential for disease modification in both lung and liver phenotypes

Read the original here:
Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic...

WARRINGTON, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that the results of its positive Phase 2 istaroxime study in early cardiogenic shock were published in the European Journal of Heart Failure (https://doi.org/10.1002/ejhf.2629). Cardiogenic shock is caused by a failing heart resulting in diminished cardiac output to the body and is characterized by very low blood pressure and hypoperfusion to end-organs. It requires urgent treatment and has a high morbidity and mortality. Windtree conducted a study called SEISMiC of istaroxime in patients experiencing early cardiogenic shock due to heart failure.

See the original post:
Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart...

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical?stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Rahsaan W. Thompson has joined the executive management team as chief legal officer. A biopharmaceutical industry veteran, Mr. Thompson has more than 20 years of experience with development stage and commercial companies.

Continue reading here:
Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer

Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024

Read the rest here:
Idera Pharmaceuticals Acquires Aceragen

Lille (France), Cambridge, MA; September 28, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe and chronic liver diseases, today announced its first half-year 2022 financial results and provided a corporate update.

View original post here:
GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update

NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Mark Frattini, M.D., Ph.D., as Chief Medical Officer, effective immediately.

Original post:
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, has filed a response to the complaint of, and counterclaims against, Janssen Biopharma in California State Superior Court for the County of San Mateo.

Read the original:
Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud

Saint Herblain (France), September 28, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the “Company”), a specialty vaccine company, today announced its intention to issue and sell, subject to market conditions, approximately $40 million of its ordinary shares in a global offering to specified categories of investors comprised of (i) a public offering of its American Depositary Shares (“ADSs”), each representing two ordinary shares, in the United States (the “U.S. Offering”) and (ii) a concurrent private placement of its ordinary shares in certain jurisdictions outside of the United States (the “European Private Placement” and together with the U.S. Offering, the “Global Offering”).

Go here to read the rest:
Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares